Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Review Article

Angiotensin receptor blockade in the challenging era of systolic hypertension

Journal of Human Hypertension volume 18, pages 837–847 (2004)Cite this article

Abstract

Systolic blood pressure is a major cardiovascular risk factor which is often associated with arterial stiffness. Markers of arterial stiffness, such as pulse pressure and carotid–femoral pulse wave velocity, have been proved independent predictors of cardiovascular risk. Recent evidence suggests that the renin–angiotensin system is involved in the pathogenesis of systolic hypertension and arterial stiffness. Outcome trials have shown impressive cardiovascular protection by reducing systolic blood pressure (BP) with drug treatment. However, in clinical practice systolic hypertension remains largely uncontrolled, first, because systolic BP goal is more difficult to be reached than diastolic and, second, because physicians are often reluctant to intensify treatment in patients with systolic BP close to 150 mmHg. Recent trials have focused on the effects of antihypertensive drugs not only on blood pressure, but also on pulse pressure and pulse-wave velocity. Blockade of the renin–angiotensin–aldosterone system, using angiotensin-converting enzyme inhibitors and more recently angiotensin receptor blockers, has been shown to provide beneficial effects on arterial stiffness that appear to be independent of their antihypertensive effects. Recent outcome trials have shown significant cardiovascular protection with angiotensin receptor blockers. These drugs have an excellent placebolike profile of adverse effects which is maintained when these drugs are combined with low-dose diuretics. Therefore, an angiotensin receptor blocker-based treatment strategy appears to be an attractive and evidence-based approach for the management of systolic hypertension, the reduction of arterial stiffness and the prevention of cardiovascular disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Guidelines Committee. European Society of Hypertension—European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  2. Chobanian A et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. Hypertension 2003; 42: 1206–1252.

    Article  CAS  PubMed  Google Scholar 

  3. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. World Health Organization, International Society of Hypertension Writing Group. J Hypertens 2003; 21: 1983–1992.

  4. Kannel WB . Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1571–1576.

    CAS  PubMed  Google Scholar 

  5. He J, Whelton PK . Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens 1999; 17(Suppl 2): S7–S13.

    CAS  Google Scholar 

  6. Kannel WB . Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile. Am Heart J 1999; 138: 205–210.

    Article  CAS  PubMed  Google Scholar 

  7. Hansson L et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–1762.

    Article  CAS  PubMed  Google Scholar 

  8. 1989 Guidelines for the management of mild hypertension: memorandum from a WHO/ISH meeting. J Hypertens 1989; 7: 689–693.

  9. The 1988 Report of the Joint National committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med 1988; 148: 1023–1038.

    Article  Google Scholar 

  10. Franklin SS et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 10: 354–360.

    Article  Google Scholar 

  11. Stamler J, Stamler R, Neaton JD . Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598–615.

    Article  CAS  PubMed  Google Scholar 

  12. Nielsen WB, Lindenstrom E, Vestbo J, Jensen GB . Is diastolic hypertension an independent risk factor for stroke in the presence of normal systolic blood pressure in the middle-aged and elderly? Am J Hypertens 1997; 10: 634–639.

    Article  CAS  PubMed  Google Scholar 

  13. Petrovitch H, Curb D, Bloom-Marcus E . Isolated systolic hypertension and risk of stroke in Japanese-American men. Stroke 1995; 26: 25–29.

    Article  CAS  PubMed  Google Scholar 

  14. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.

  15. Staessen JA et al. For the Systolic Hypertension in Europe Trial Investigators. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 650: 757–764.

    Article  Google Scholar 

  16. Whyte JL, Lapuerta P, L'Italien GJ, Franklin SS . The challenge of controlling systolic blood pressure: data from the National Health and Nutrition Examination Survey (NHANES III), 1988–1994. J Clin Hypertens 2001; 3: 211–216.

    Article  CAS  Google Scholar 

  17. Hyman DJ, Pavlik VN . Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479–486.

    Article  CAS  PubMed  Google Scholar 

  18. Berlowitz DR et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957–1963.

    Article  CAS  PubMed  Google Scholar 

  19. Oliveria SA et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162: 413–420.

    Article  PubMed  Google Scholar 

  20. Fagard RH, Van Den Enden M, Leeman M, Warling X . Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297–1302.

    Article  CAS  PubMed  Google Scholar 

  21. Stergiou GS, Karotsis AK, Symeonidis A, Vassilopoulou VA, for the ABC-GP Study Group. Aggressive blood pressure Control in General Practice (ABC-GP) study: can the new targets be reached? J Hum Hypertens 2003; 17: 767–773.

    Article  CAS  PubMed  Google Scholar 

  22. Mancia G, Grassi G . Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20: 1461–1464.

    Article  CAS  PubMed  Google Scholar 

  23. Julius S et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544–548.

    Article  PubMed  Google Scholar 

  24. Benetos A . Pulse pressure and cardiovascular risk. J Hypertens 1999; 17(Suppl 5): S21–S24.

    CAS  Google Scholar 

  25. Blacher J et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085–1089.

    Article  CAS  PubMed  Google Scholar 

  26. Madhavan S, Ooi WL, Cohen H, Alderman MH . Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395–401.

    Article  CAS  PubMed  Google Scholar 

  27. Fang J, Madhavan S, Cohen H, Alderman MH . Measures of blood pressure and myocardial infarction in treated hypertensive patients. J Hypertens 1995; 13: 413–419.

    Article  CAS  PubMed  Google Scholar 

  28. Millar JA, Lever AF . Pulse pressure predicts coronary but not cerebrovascular events in placebo-treated male subjects of MRC trial. J Hypertens 1996; 14(Suppl 1): S194.

    Google Scholar 

  29. Kostis JB et al. Association of increased pulse pressure with the development of heart failure in SHEP. Systolic Hypertension in the Elderly (SHEP) Cooperative Research Group. Am J Hypertens 2001; 14: 798–803.

    Article  CAS  PubMed  Google Scholar 

  30. Amery A et al. Mortality and morbidity results from the European Working Party on high blood pressure in the elderly trial. Lancet 1985; 1: 1349–1354.

    Article  CAS  PubMed  Google Scholar 

  31. Mitchell GF et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and ventricular enlargement. Circulation 1997; 96: 4254–4260.

    Article  CAS  PubMed  Google Scholar 

  32. Benetos A et al. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410–1415.

    Article  CAS  PubMed  Google Scholar 

  33. Verdecchia P et al. Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertension. Circulation 2001; 103: 2579–2584.

    Article  CAS  PubMed  Google Scholar 

  34. Selker HP, Beshansky J, Schmid CH . Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic predictive instrument (TPI) project result. Circulation 1994; 90: 1657–1661.

    Article  CAS  PubMed  Google Scholar 

  35. Franklin SS et al. The importance of pulsatile components of hypertension in predicting carotid stenosis in older adults. J Hypertens 1997; 15: 1143–1150.

    Article  CAS  PubMed  Google Scholar 

  36. Pannier B et al. Pulse pressure and echocardiographic findings in essential hypertension. J Hypertens 1989; 7: 127–132.

    Article  CAS  PubMed  Google Scholar 

  37. Pedrinelli R et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000; 35: 48–54.

    Article  CAS  PubMed  Google Scholar 

  38. Stergiou GS et al. Clinic, home and ambulatory pulse pressure: comparison and reproducibility. J Hypertens 2002; 20: 1987–1993.

    Article  CAS  PubMed  Google Scholar 

  39. Verdecchia P et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 1998; 32: 983–988.

    Article  CAS  PubMed  Google Scholar 

  40. London GM, Cohn JN . Prognostic application of arterial stiffness. Am J Hypertens 2002; 15: 754–758.

    Article  PubMed  Google Scholar 

  41. Achimastos A et al. Determinants of arterial stiffness in Greek and French hypertensive men. Blood Press 2002; 11: 218–222.

    Article  PubMed  Google Scholar 

  42. O'Rourke MF et al. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens 2002; 15: 426–444.

    Article  PubMed  Google Scholar 

  43. Laurent S et al. Clinical applications of arterial stiffness: therapeutics and pharmacology. Am J Hypertens 2002; 15: 453–458.

    Article  PubMed  Google Scholar 

  44. Safar ME, Benetos A . Factors influencing arterial stiffness in systolic hypertension in the elderly: role of sodium and the renin–angiotensin system. Am J Hypertens 2003; 16: 249–258.

    Article  CAS  PubMed  Google Scholar 

  45. Van Bortel LM et al. Clinical applications of arterial stiffness, Task Force III: recommendations for user procedures. Am J Hypertens 2002; 15: 445–452.

    Article  PubMed  Google Scholar 

  46. Boutouyrie P et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10–15.

    Article  CAS  PubMed  Google Scholar 

  47. Laurent S et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236–1241.

    Article  CAS  PubMed  Google Scholar 

  48. Blacher J et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999; 33: 1111–1117.

    Article  CAS  PubMed  Google Scholar 

  49. Safar ME, Van Bortel LMAB, Struijker-Boudier HAJ . Resistance and conduit arteries following converting enzyme inhibition in hypertension. J Vasc Res 1997; 34: 67–81.

    Article  CAS  PubMed  Google Scholar 

  50. Rehman A, Rahman AR, Rasool AH . Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT-1) receptors. J Hum Hypertens 2002; 16: 261–266.

    Article  CAS  PubMed  Google Scholar 

  51. Safar ME, Levy BI, Struijker-Boudier H . Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864–2869.

    Article  PubMed  Google Scholar 

  52. Mourad JJ et al. Age-related increase of pulse pressure and gene polymorphisms in essential hypertension: a preliminary study. JRAAS 2002; 3: 109–115.

    CAS  PubMed  Google Scholar 

  53. Benetos A et al. Influence of the angiotensin type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension 1996; 28: 1081–1084.

    Article  CAS  PubMed  Google Scholar 

  54. Asmar R et al. Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. JRAAS 2002; 3: 176–180.

    CAS  PubMed  Google Scholar 

  55. Asmar R, Lacourciere Y . A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators. J Hypertens 2000; 18: 1683–1690.

    Article  CAS  PubMed  Google Scholar 

  56. Stergiou GS et al. Assessment of drug effects on blood pressure and pulse pressure using measurements in the clinic, at home and with ambulatory monitoring. J Hum Hypertens 2002; 16: 729–735.

    Article  CAS  PubMed  Google Scholar 

  57. Stergiou GS, Efstathiou SP, Roussias LG, Mountokalakis TD . Blood pressure- and pulse pressure-lowering effects, trough:peak ratio and smoothness index of telmisartan compared to lisinopril. J Cardiovasc Pharmacol 2003; 42: 491–496.

    Article  CAS  PubMed  Google Scholar 

  58. Delerme S et al. Aortic stiffness is reduced beyond blood pressure lowering by short- and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients (abst). Hypertension 1998; 32: 789.

    Google Scholar 

  59. Morgan T, Lauri J, Bertram D, Anderson A . Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118–123.

    Article  CAS  PubMed  Google Scholar 

  60. Cockcroft JR, Brown MJ . Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study. Lancet 2002; 359: 2203–2204.

    Article  Google Scholar 

  61. Kelly R et al. Arterial dilation and reduced wave reflection: benefit of dilevalol in hypertension. Hypertension 1989; 14: 14–21.

    Article  CAS  PubMed  Google Scholar 

  62. Cockcroft JR et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067–1071.

    CAS  PubMed  Google Scholar 

  63. Asmar RG et al. Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 1988; 78: 941–950.

    Article  CAS  PubMed  Google Scholar 

  64. Asmar R et al. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. J Hypertens 2001; 19: 813–818.

    Article  CAS  PubMed  Google Scholar 

  65. Ghiadoni L et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281–1286.

    Article  CAS  PubMed  Google Scholar 

  66. Asmar RG, London GM, O'Rourke ME, Safar ME . REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38: 922–926.

    Article  CAS  PubMed  Google Scholar 

  67. London GM, Asmar RG, O'Rourke MF, Safar ME . REASON Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. Am Coll Cardiol 2004; 43: 92–99.

    Article  CAS  Google Scholar 

  68. Navalkar S, Parthasarathy S, Santanam N, Khan BV . Irbesartan, an AT1 receptor antagonist, reduces markers of inflammation in patients with early atherosclerosis. J Am Coll Cardiol 2001; 37: 440.

    Article  CAS  PubMed  Google Scholar 

  69. Lauten WB et al. Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. Am J Cardiol 2003; 91: 1116–1119.

    Article  CAS  PubMed  Google Scholar 

  70. Koh KK et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905–910.

    Article  CAS  PubMed  Google Scholar 

  71. Shargorodsky M et al. Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension. Am J Hypertens 2002; 15: 1087–1091.

    Article  CAS  PubMed  Google Scholar 

  72. Klemsdal TO, Moan A, Kjeldsen SE . Effects of selective angiotensin II type 1 receptor blockade with losartan on arterial compliance in patients with mild essential hypertension. Blood Press 1999; 8: 214–219.

    Article  CAS  PubMed  Google Scholar 

  73. Mahmud A, Feely J . Effect of angiotensin ii receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens 2002; 15: 1092–1095.

    Article  CAS  PubMed  Google Scholar 

  74. Rajzer M, Klocek M, Kawecka-Jaszcz K . Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertens 2003; 16: 439–444.

    Article  CAS  PubMed  Google Scholar 

  75. Takami T, Shigemasa M . Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003; 26: 609–614.

    Article  CAS  PubMed  Google Scholar 

  76. Mahmud A, Feely J . Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002; 15: 321–325.

    Article  CAS  PubMed  Google Scholar 

  77. Cohn JN, Tognoni G . Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675.

    Article  CAS  PubMed  Google Scholar 

  78. Pfeffer MA et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766.

    Article  CAS  PubMed  Google Scholar 

  79. Pitt B et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–1587.

    Article  CAS  PubMed  Google Scholar 

  80. Pfeffer MA et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906.

    Article  CAS  PubMed  Google Scholar 

  81. Dickstein K, Kjekshus J . OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–760.

    Article  CAS  PubMed  Google Scholar 

  82. Dahlöf B et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

    Article  PubMed  Google Scholar 

  83. Lewis E et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

    Article  CAS  PubMed  Google Scholar 

  84. Brenner B et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

    Article  CAS  PubMed  Google Scholar 

  85. Parving HH et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.

    Article  CAS  PubMed  Google Scholar 

  86. Blood Pressure Lowering Treatment Trialists. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–1535.

  87. Neutel JM et al. The effects of candesartan cilexetil in isolated systolic hypertension: a Clinical Experience Trial. J Clin Hypertens 2000; 2: 181–186.

    CAS  Google Scholar 

  88. Cushman WC, Brady WE, Gazdick LP, Zeldin RK . The effect of a losartan-based treatment regimen on isolated systolic hypertension. J Clin Hypertens 2002; 4: 101–107.

    Article  CAS  Google Scholar 

  89. Volpe M et al. Comparison of the blood pressure-lowering effects and tolerability of losartan and amlodipine based regimens in patients with isolated systolic hypertension. Clin Ther 2003; 25: 1469–1489.

    Article  CAS  PubMed  Google Scholar 

  90. Neutel JM, Bedigian MP . Efficacy of valsartan in patients aged > or =65 years with systolic hypertension. Clin Ther 2000; 22: 961–969.

    Article  CAS  PubMed  Google Scholar 

  91. Kjeldsen SE et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491–1498.

    Article  CAS  PubMed  Google Scholar 

  92. Malmqvist K et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167–1176.

    Article  CAS  PubMed  Google Scholar 

  93. Thurmann PA et al. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037–2042.

    Article  CAS  PubMed  Google Scholar 

  94. Gaudio C et al. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J Cardiovasc Pharmacol 2003; 42: 622–628.

    Article  CAS  PubMed  Google Scholar 

  95. Stergiou GS, Skeva II . Renin–angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences. Curr Top Med Chem 2004; 4: 473–481.

    Article  CAS  PubMed  Google Scholar 

  96. Mogensen CE et al. Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440–1444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Azizi M et al. Pilot study of combined blockade of the renin–angiotensin system in essential hypertensive patients. J Hypertens 2000; 18: 1139–1147.

    Article  CAS  PubMed  Google Scholar 

  98. Stergiou GS et al. Additive hypotensive effect of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in essential hypertension. J Cardiovasc Pharmacol 2000; 35: 937–941.

    Article  CAS  PubMed  Google Scholar 

  99. Stergiou GS et al. Additive effects of an ACE inhibitor versus a calcium antagonist versus a diuretic in hypertensive patients uncontrolled on angiotensin receptor blocker monotherapy. Abstract. J Hypertens 2004; 22(Suppl 2): S318.

    Article  Google Scholar 

  100. Sever PS, Chang CL . Discordant responses to two classes of drugs acting on the renin–angiotensin system. JRAAS 2001; 2: 25–30.

    CAS  PubMed  Google Scholar 

  101. Stergiou GS et al. Does the antihypertensive response to angiotensin converting enzyme inhibition predict the antihypertensive response to angiotensin receptor antagonism? Am J Hypertens 2001; 14: 688–693.

    Article  CAS  PubMed  Google Scholar 

  102. Stergiou G, Efstathiou S, Roussias L, Mountokalakis T . Intraindividual blood pressure responses to angiotensin converting enzyme inhibition and angiotensin receptor blockade. Am J Hypertens 2004; 17: 123A.

    Article  Google Scholar 

  103. Gradman AH et al. Comparative effects of candesartan cilexetil and losartan in patients with systemic hypertension. Candesartan Versus Losartan Efficacy Comparison (CANDLE) Study Group. Heart Dis 1999; 1: 52–57.

    CAS  PubMed  Google Scholar 

  104. Smith DH et al. Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies. Blood Press Monit 2003; 8: 111–117.

    Article  PubMed  Google Scholar 

  105. Kassler-Taub K et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan Study Investigators. Am J Hypertens 1998; 11: 445–453.

    Article  CAS  PubMed  Google Scholar 

  106. Mancia G et al. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135–142.

    Article  PubMed  Google Scholar 

  107. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.

  108. Messerli FH, Grossman E, Goldbourt U . Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903–1907.

    Article  CAS  PubMed  Google Scholar 

  109. Conlin PR et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418–426.

    Article  CAS  PubMed  Google Scholar 

  110. Howe P, Phillips P, Saini R, Kassler-Taub K . The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens 1999; 21: 1373–1396.

    Article  CAS  PubMed  Google Scholar 

  111. Raskin P et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999; 13: 683–687.

    Article  CAS  PubMed  Google Scholar 

  112. Kochar M et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797–805.

    Article  CAS  PubMed  Google Scholar 

  113. Brown MJ et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension 2000; 35: 1038–1042.

    Article  CAS  PubMed  Google Scholar 

  114. Morgan T, Anderson A . A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension. Am J Hypertens 2002; 15: 544–549.

    Article  CAS  PubMed  Google Scholar 

  115. Farsang C et al. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest 2001; 21: 17–23.

    Article  CAS  Google Scholar 

  116. Zanchetti A . Contribution of fixed low-dose combinations to initial therapy in hypertension. Eur Heart J 1999; 17(Suppl A): 8–15.

    Google Scholar 

  117. Stergiou GS, Malakos JS, Achimastos AD, Mountokalakis TD . Additive hypotensive effect of a dihydropyridine calcium antagonist to that produced by a thiazide diuretic: a double-blind placebo-controlled crossover trial with ambulatory blood pressure monitoring. J Cardiovasc Pharmacol 1997; 29: 412–416.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Third University Department of Medicine, Hypertension Center, Sotiria Hospital, Athens, Greece

    G S Stergiou

Authors
  1. G S Stergiou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G S Stergiou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stergiou, G. Angiotensin receptor blockade in the challenging era of systolic hypertension. J Hum Hypertens 18, 837–847 (2004). https://doi.org/10.1038/sj.jhh.1001762

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001762

Keywords

This article is cited by

Search

Advanced search

Quick links